Immuron Ltd

IMRN

Explore Our Financial Data > Companies > Immuron Ltd

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	IMRN
CIK	0001660046
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	62 LYGON STREET, LEVEL 3, CARLTON, VICTORIA, C3, 3053
Website	immuron.com.au
Phone	61 03 9824 5254
CEO	Steven Lydeamore
Employees	5

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$3.27 million
Pre-Tax Income	$-4.63 million
Net Income	$-4.63 million
Net Income to Common	$-4.26 million
EPS	N/A

View All

Balance Sheet

Cash	$7.78 million
Assets	$10.38 million
Liabilities	$1.90 million
Common Equity	$8.49 million
Liabilities & Equity	$10.38 million

View All

Cash Flow Statement

Net Income	$-4.63 million
Cash From Operating Activities	$-3.93 million
Cash From Investing Activities	$218,712.00
Cash From Financing Activities	$554.00
Change in Cash	$-3.71 million

View All

Calculations

NOPAT	$-2.71 million
EBITDA	$-4.85 million
Price to Earnings	N/A
Price to Book	$1.13
ROE	-42.97%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Immuron - FY25 global sales exceed projection, up 49% on prior year

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior yearJune 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globa

Article Link

Immuron Letter to Shareholders: Projects Update

Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan® clinical study in October 2025Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025Launch plans underway for ProIBS® in AustraliaImmuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 MELBOURNE, Australia, May 30, 2025 (GLOBE NEWSWIRE) -- Immuron

Article Link

Immuron Travelan® highest sales in history

Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE

Article Link

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will joi

Article Link

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

Article Link